Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Aarti Drugs Ltd Performance

Today's Low
485.55
arrowIcon
Today's High
499.10
52 Wk Low
409.00
arrowIcon
52 Wk High
645.75


Open

490

Traded Value (Cr)

5.19 Cr

Prev. Close

492.35

VWAP

493.98

Volume

1,10,702

Face Value

10

Aarti Drugs Ltd Fundamentals

Market Cap
₹ 4,665 Cr
P/E Ratio (TTM)
25.89
P/B Ratio
3.86
Debt to Equity
0.49
ROE
14.90 %
EPS (TTM)
19.60
Dividend Yield
0.20%
Book Value
131.55

Click here to know more about Fundamentals

Aarti Drugs Ltd Financials

Aarti Drugs Ltd Financials

Aarti Drugs Ltd Shareholding Pattern

Held By Dec 2023 Sep 2023 Jun 2023 Mar 2023
Promoters 57.47 % 58.56 % 58.70 % 59.58 %
Retail 25.84 % 24.65 % 25.34 % 25.72 %
Others 9.41 % 9.24 % 9.36 % 8.75 %
Mutual Funds 5.18 % 5.22 % 4.63 % 4.01 %
FII 2.10 % 2.33 % 1.96 % 1.94 %

Promoters

57.47%

Retail

25.84%

Others

9.41%

Mutual Funds

5.18%

FII

2.10%

Promoters

58.56%

Retail

24.65%

Others

9.24%

Mutual Funds

5.22%

FII

2.33%

Promoters

58.70%

Retail

25.34%

Others

9.36%

Mutual Funds

4.63%

FII

1.96%

Promoters

59.58%

Retail

25.72%

Others

8.75%

Mutual Funds

4.01%

FII

1.94%

Resistance and Support

₹493.75

PIVOT

resistance-arrow
Resistance
First Resistance₹500.450
Second Resistance₹506.150
Third Resistance₹512.850
support-arrow
Support
First Resistance₹488.050
Second Resistance₹481.350
Third Resistance₹475.650
RSI71.238
MACD27.245
ADX20.354
CCI57.703

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day110,70245,66943.53
Week115,81167,49856.21
1 Month260,286113,78246.97
6 Months110,70244,32040.04

About Aarti Drugs Ltd

Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra. It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries, Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries. The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs), Steroids, Pharmaceutical Intermediates, and Specialty Chemicals, such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in September 28th, 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 1994-95, the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also, Rupal Chemical Industries, a group company, was amalgamated with the company. During the year 1996-97, the company started their production of secnidazole and dichlofenac sodium. During the year 2000-01, they started the commercial production of Pharmaceutical Ingredients. During the year 2002-03, the company expanded the production capacity of bulk drugs by 598,000 kg to 17,430,000 kg. During the year 2003-04, the company further expanded the production capacity of bulk drugs by 588,000 kg to 18,018,000 kg. During the year 2004-05, the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 2005-06, the company increased the production capacity of Pharmaceutical by 2,325,000 kg to 24,020,000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also, they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company. During the year 2006-07, the company increased the production capacity by 570,000 kg to 24,590,000 kg. During the next year, they increased the production capacity by 399,000 kg to 24,989,000 kg. During the year 2008-09, they further increased the production capacity of Pharmaceutical by 50,000 kg to 25,000,000 kg. During the year 2009-10, the company carried out process improvement work in bulk drugs, such as antihistaminic/anti-allergic, anti-inflammatory and anti-diabetic. ADL expanded the production capacity from 25,000,000 kg to 25,716,000 kg. A Scheme of Amalgamation of Suyash Laboratories Ltd., wholly owned subsidiary of the Company, with the Company became operative w.e.f. from 6th July, 2012. During year 2015, Company acquired 100% equity shares in Pinnacle Life Science Pvt. Ltd., situated at Baddi, Himachal Pradesh. During year 2020, Company incorporated 2 overseas Subsidiaries and 1 Domestic subsidiary Company. Pinnacle Chile SpA, incorporated in Santiago, Chile, was established for marketing the formulation of drugs and participating in the tender and private market in Chile. Aarti Speciality Chemicals Limited (Wholly Owned Subsidiary), in Mumbai, was carrying on business of manufacturers, producers, processors, buyers, sellers, importers, exporters or otherwise dealers in Speciality and other chemicals, pharmaceutical and drugs. In 2022, the Company commissioned brownfield expansion of Speciality Chemical Plant at Tarapur, which turned operational effective from May 2022.

Managing Director

Prakash M Patil

Founded

1984

NSE Symbol

AARTIDRUGS

Aarti Drugs Ltd Management

NameDesignation
Prakash M PatilCMD & Executive Director
Rashesh C GogriED / MD / Promoter
Harshit M SavlaED / Joint MD / Promoter
Harit P ShahE D & Wholetime Director
Uday M PatilWTD & Executive Director
Narendra Jagannath SalviNon Executive Director
Navin Chapshi ShahIndependent Non Exe. Director
Krishnacharya G AkamanchiIndependent Non Exe. Director
Priti SavlaIndependent Non Exe. Director
Ankit Vikram PalejaIndependent Non Exe. Director
Bhaskar Narayan ThoratIndependent Non Exe. Director
Neha GadaIndependent Non Exe. Director

Aarti Drugs Ltd News

Aarti Drugs reports PAT of Rs 37 cr in Q3 FY24
The pharmaceutical company’s consolidated net profit rose marginally to Rs 36.71 crore in Q3 FY24 as compared with Rs 36.67 crore recorded in Q3 FY23.
Board of Aarti Drugs recommends interim dividend
Of Rs 1 per share
Aarti Drugs consolidated net profit declines 0.03% in the December 2023 quarter
Sales decline 8.74% to Rs 605.94 crore
Aarti Drugs standalone net profit declines 13.87% in the December 2023 quarter
Sales decline 13.96% to Rs 538.21 crore
Aarti Drugs to table results
On 24 January 2024
Aarti Drugs consolidated net profit rises 2.17% in the September 2023 quarter
Sales decline 6.71% to Rs 641.54 crore
Aarti Drugs to table results
On 19 October 2023
Aarti Drugs AGM scheduled
On 26 September 2023
Volumes spurt at Aarti Drugs Ltd counter
Aarti Drugs Ltd registered volume of 98.39 lakh shares by 14:14 IST on NSE, a 11.53 fold spurt over two-week average daily volume of 8.53 lakh shares
Aarti Drugs Ltd leads gainers in 'A' group
SJVN Ltd, Dhani Services Ltd, Action Construction Equipment Ltd and Jain Irrigation Systems Ltd are among the other gainers in the BSE's 'A' group today, 24 July 2023.

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,65,370 Cr
₹ 1,522.80
(0.42 %)
88.68
CIPLA₹ 1,08,655 Cr
₹ 1,345.75
(-0.12 %)
33.03
DRREDDY₹ 99,137 Cr
₹ 5,942.85
(-0.24 %)
24.91
DIVISLAB₹ 97,472 Cr
₹ 3,671.70
(-1.00 %)
71.41
MANKIND₹ 93,635 Cr
₹ 2,337.45
(-2.43 %)
56.69

Aarti Drugs Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Aarti Drugs Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Aarti Drugs Ltd's share price is ₹495.00 as of April 19, 2024

Aarti Drugs Ltd's P/E ratio is 25.89 times as of April 19, 2024.

Aarti Drugs Ltd's most recent financial reports indicate a price-to-book ratio of 3.86, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Aarti Drugs Ltd's market is 4,666 Cr as on April 19, 2024.

The current financial records of Aarti Drugs Ltd show a 14.90% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Aarti Drugs Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Aarti Drugs Ltd's 52-week high and low as of April 19, 2024 are ₹499.1 and ₹485.55 respectively.

As of the Dec 2023 quarter, the promoter shareholding in Aarti Drugs Ltd stands at 57.47%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 2.33% to 2.10%.